Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Bluebird

Bluebird’s gene therapy for brain disease receives accelerated approval

Bluebird Bio Inc.’s gene therapy for a brain-wasting disease received accelerated approval from U.S. regulators, making it the first treatment of its kind for children living with cerebral adrenoleukodystrophy.

Tribune News Service

FDA Okays bluebird bio's $3M Gene Therapy For Rare Neurological Disorder In Boys: What Investors Should Know

FDA Okays bluebird bio's $3M Gene Therapy For Rare Neurological Disorder In Boys: What Investors Should Know

Biotechnology company, bluebird bio, Inc. (NASDAQ: BLUE) announced late Friday that the Food and Drug Administration approved its gene therapy for a rare neurodegenerative disease.

Michael Hiltzik: This life-saving drug will cost a record $2.8 million. Who will pay the price?

For the estimated 1,500 Americans suffering from a blood disorder known as beta thalassemia, the Food and Drug Administration's approval Aug. 17 of the drug Zynteglo was almost unalloyed good news.

Los Angeles Times

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Cardiff City transfer news as Morison delivers verdict on signing left-back cover with recruitment team 'working incredibly hard'

The latest Bluebirds news from Cardiff City Stadium

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. Bluebird shares traded in a range of $6.13 to $8.18 on a day…

Cardiff City transfer news as fans want Sean Morrison to sign new deal and verdict given on West Brom loanee joining permanently

The latest Bluebirds news from Cardiff City Stadium

Cardiff City transfer headlines as Morison says more signings will increase competition and trialists score in game today

The latest Bluebirds headlines from Cardiff City Stadium

inkl

Read news from The Economist, FT, and more,
with one subscription

Cardiff City notebook as wide men excite, new signing is coolness personified and another midfield concern emerges

Cardiff City notebook as wide men excite, new signing is coolness personified and another midfield concern emerges

The Bluebirds drew with Shrewsbury Town on Tuesday night and these are the main takeways

Cardiff City transfer news as Josh Murphy axed from Reading trial and update given on Shrewsbury Town game

Cardiff City transfer news as Josh Murphy axed from Reading trial and update given on Shrewsbury Town game

The latest Bluebirds news from Cardiff City Stadium

Cardiff City transfer news as Romaine Sawyers reveals 'sad' West Brom exit and goalkeeper situation explained

Cardiff City transfer news as Romaine Sawyers reveals 'sad' West Brom exit and goalkeeper situation explained

The latest Bluebirds transfer news from Cardiff City Stadium

Cardiff City's lopsided and one-paced squad is now unrecognisable after transfer flurry but final jigsaw piece will make or break season

Cardiff City's lopsided and one-paced squad is now unrecognisable after transfer flurry but final jigsaw piece will make or break season

The Bluebirds' work in this transfer window has been swift and much-needed, but more must be done before the season kicks off in earnest

Something's got to give at Cardiff City as new arrivals push Bluebirds to limit

Something's got to give at Cardiff City as new arrivals push Bluebirds to limit

The Bluebirds have confirmed the appointment of new coaches on Wednesday morning and one will certainly have his work cut out for him in the coming weeks

Bluebird Bio Secures FDA Advisory Committee's Endorsement For Neurodegenerative Disease Drug

Bluebird Bio Secures FDA Advisory Committee's Endorsement For Neurodegenerative Disease Drug

FDA Sounds Positive On Bluebird's One Gene Therapy But Doubts Another

FDA Sounds Positive On Bluebird's One Gene Therapy But Doubts Another

The FDA signaled in briefing documents released that it may approve Bluebird bio Inc's (NASDAQ:BLUE) beti-cel gene therapy to treat β-thalassemia for those who require regular blood transfusions. The Prescription Drug User Fee Act (PDUFA) goal dates for beti-cel and eli-cel are August 19 and September 16. Bluebird bio's blood disorder treatment demonstrates "clinically meaningful"…

Get all your
news in one place.

100's of premium titles.
One news app.

Cardiff City transfer news as boss wants Bluebirds starlet back, Morison issues vow over signings and target offered deal

The latest Bluebirds transfer news from Cardiff City Stadium

Bluebird Bio Joins Layoff Band Wagon As Gene Therapy Biotech Cuts Staff To Reduce Costs

Bluebird Bio Inc (NASDAQ:BLUE) is laying off about 30% of its workforce before the FDA decides the fate of two of its gene therapies. The gene therapy-focused company is showing the exit to nearly one-third of its staff to extend its cash runway into the first half of 2023 and save $160 million…

AST SpaceMobile Collaborates With Orange

AST SpaceMobile Inc (NASDAQ:ASTS) has entered a non-binding memorandum of understanding with Orange SA (NYSE:ORAN). The companies will examine the opportunity for Orange to test the SpaceMobile service in one African country, following AST SpaceMobile's planned launch of BlueWalker 3. BlueWalker 3 is ASTS's test satellite with an aperture of 693 square feet, designed to…

Twitter Names New Leaders For Consumer Division

Twitter Inc (NYSE:TWTR) named new leaders in its consumer division, Bluebird, to develop new features and services. Jay Sullivan, who led product for Meta Platforms Inc (NASDAQ:FB) Facebook's AI Assistant, and led the privacy and safety product teams on Messenger and Instagram Direct, joined Twitter late last year as the new head of product in…

Get all your
news in one place.

100's of premium titles.
One news app.

Why Bluebird Bio Shares Are Tumbling Today

Hit by several delays for its gene therapy programs, Bluebird bio Inc (NASDAQ: BLUE) ended 2021 with a cash and equivalents balance of

Cardiff City headlines as Morison names points total to avoid relegation and Bothroyd praises Watters' reaction

The latest Bluebirds news from Cardiff City Stadium

Cardiff City's unsung hero impresses everyone after being 'shocked' by club's decision to send him away

The Bluebirds signed him last summer and then loaned him out immediately and watched as he flourished away from Cardiff City Stadium

FDA Pushes Review Period For Bluebird bio's Neurodegenerative Disease, Thalassemia Gene Therapies

1 2

People

Cesar Azpilicueta

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

European Commission

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Prescription Drug

Sickle Cell Disease

Places

404,529 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play